These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

594 related articles for article (PubMed ID: 30859681)

  • 1. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
    Van den Bossche J; Deben C; De Pauw I; Lambrechts H; Hermans C; Deschoolmeester V; Jacobs J; Specenier P; Pauwels P; Vermorken JB; Peeters M; Lardon F; Wouters A
    Mol Oncol; 2019 May; 13(5):1196-1213. PubMed ID: 30859681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
    Ferrarotto R; Goonatilake R; Yoo SY; Tong P; Giri U; Peng S; Minna J; Girard L; Wang Y; Wang L; Li L; Diao L; Peng DH; Gibbons DL; Glisson BS; Heymach JV; Wang J; Byers LA; Johnson FM
    Clin Cancer Res; 2016 Apr; 22(7):1674-1686. PubMed ID: 26597303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
    Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibiting polo-like kinase 1 enhances radiosensitization via modulating DNA repair proteins in non-small-cell lung cancer.
    Yao D; Gu P; Wang Y; Luo W; Chi H; Ge J; Qian Y
    Biochem Cell Biol; 2018 Jun; 96(3):317-325. PubMed ID: 29040814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polo-like kinase 1 as a promising diagnostic biomarker and potential therapeutic target for hepatocellular carcinoma.
    Yousef EH; El-Mesery ME; Habeeb MR; Eissa LA
    Tumour Biol; 2020 Apr; 42(4):1010428320914475. PubMed ID: 32252611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1.
    Liu J; Lu KH; Liu ZL; Sun M; De W; Wang ZX
    BMC Cancer; 2012 Nov; 12():519. PubMed ID: 23151088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
    Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
    Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer.
    Wang Y; Wu L; Yao Y; Lu G; Xu L; Zhou J
    Cancer Lett; 2018 Nov; 436():1-9. PubMed ID: 30118839
    [TBL] [Abstract][Full Text] [Related]  

  • 9.  p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors.
    Sanhaji M; Kreis NN; Zimmer B; Berg T; Louwen F; Yuan J
    Cell Cycle; 2012 Feb; 11(3):543-53. PubMed ID: 22262171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells.
    Park S; Kim TM; Cho SY; Kim S; Oh Y; Kim M; Keam B; Kim DW; Heo DS
    Cancer Lett; 2020 Dec; 495():135-144. PubMed ID: 32979462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells.
    Choi M; Kim W; Cheon MG; Lee CW; Kim JE
    Cancer Lett; 2015 Feb; 357(2):591-601. PubMed ID: 25524551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric Malignancies.
    Abbou S; Lanvers-Kaminsky C; Daudigeos-Dubus E; LE Dret L; Laplace-Builhe C; Molenaar J; Vassal G; Geoerger B;
    Anticancer Res; 2016 Feb; 36(2):599-609. PubMed ID: 26851014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.
    Nguyen T; Parker R; Hawkins E; Holkova B; Yazbeck V; Kolluri A; Kmieciak M; Rahmani M; Grant S
    Oncotarget; 2017 May; 8(19):31478-31493. PubMed ID: 28416758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor.
    Van den Bossche J; Lardon F; Deschoolmeester V; De Pauw I; Vermorken JB; Specenier P; Pauwels P; Peeters M; Wouters A
    Med Res Rev; 2016 Jul; 36(4):749-86. PubMed ID: 27140825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.
    Lin YC; Sun SH; Wang FF
    Cell Signal; 2011 Nov; 23(11):1816-23. PubMed ID: 21726628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines.
    Münch C; Dragoi D; Frey AV; Thurig K; Lübbert M; Wäsch R; Bogatyreva L; Hauschke D; Lassmann S; Werner M; May AM
    Leuk Res; 2015 Apr; 39(4):462-70. PubMed ID: 25697066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53.
    Sanhaji M; Louwen F; Zimmer B; Kreis NN; Roth S; Yuan J
    Cell Cycle; 2013 May; 12(9):1340-51. PubMed ID: 23574746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-canonical cMet regulation by vimentin mediates Plk1 inhibitor-induced apoptosis.
    Singh R; Peng S; Viswanath P; Sambandam V; Shen L; Rao X; Fang B; Wang J; Johnson FM
    EMBO Mol Med; 2019 May; 11(5):. PubMed ID: 31040125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of Polo-like kinase 1 induces cellular senescence in human primary cells through a p53-dependent pathway.
    Kim HJ; Cho JH; Kim JR
    J Gerontol A Biol Sci Med Sci; 2013 Oct; 68(10):1145-56. PubMed ID: 23525475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Large-scale label-free comparative proteomics analysis of polo-like kinase 1 inhibition via the small-molecule inhibitor BI 6727 (Volasertib) in BRAF(V600E) mutant melanoma cells.
    Cholewa BD; Pellitteri-Hahn MC; Scarlett CO; Ahmad N
    J Proteome Res; 2014 Nov; 13(11):5041-50. PubMed ID: 24884503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.